Abstract:
Background:
Even if the romanian population is ethnically compact caucasian-type population, many of the patients referred for bone marrow transplantation lack a suitable donor. In order to expand the donor pool and the accesibility to transplant procedure for those who have indications it is necessary to introduce the haplo-identical bone marrow transplant procedure with myeloablative and reducedintensity conditioning in Fundeni Clinical Institute.
Introduction:
Bone marrow transplantation is the only curative option for many adult hematological malignancies. Donor availability in a timely manner for those patients is one of the major challenge in the treatment. The likelihood of finding an HLA-matched sibling donor (MSD) for a patient is 25% as the mendelian rule shows, and the fact that in Romania we have more and more families with only one child, making the sibling-donor search more and more difficult. Since 2009 Romania established a National Volunteer Stem Cell Donor Registry (RNDVCSH) and the goal was to enlarge the possibility to find HLA-matched unrelated donors (MUD) for patients. This approach offered transplant for only up to 60%patients referred for transplantation in 2014, even we chose one HLA-mismatch donors. For these reasons it is important to introduce HLA-haploidentical transplantation.
Potential HLA-haploidentical donors include biological parents or children of a patient, and each sibling has a 50% chance of sharing one HLA-haplotype. So it is a rapid possibility to find a donor and it will be available in very short time for the transplant. The major drawback is the intense bidirectional alloreactivity with graft failure and graft versus host disease (GVHD), who leads to increased non-relapse mortality (NRM). Initially in haplo-setting, knowing that T-cells are responsible in graft versus host disease (GVHD), studies were made removing T cells from the donor graft ex-vivo. But the graft failure increased. The post-transplant high-dose Cyclophosphamide (PTCy) it was the next step in order to deplete in-vivo alloreactive T cells from the donor and the host at the same time, and reduce both GVHD and rejection. This DNA-damaging agent take action over the proliferative, alloreactive T cells, but not over resting T cells and allow a better immune reconstitution and lower non-relapse mortality (NRM).
Patient eligibility
Patients over 18 years of age and under 65, with a diagnosis of hematological malignancy, having an indication for allogeneic transplant within the Fundeni Clinical Institute local practice. The eligibility should be assessed by the Fundeni Clinical Institute transplant committee after the hematology specialist fulfilled the transplant-specific medical chart of the patient. The patient must have one or more potential related mismatched donor (biological parents, siblings or children) typed in high-resolution for HLA-A, -B, -C, -DRB1 and -DPB1.
The exclusion criterias are: a) hematological malignancy in evolution b) suitable matched sibling or unrelated donor, defined by local committee c) prior autologous stem cell transplantation, if the disease relapse under 6 months after autologous transplant. d) prior allogeneic stem cell transplant e) poor performance status: Karnofsky under 70% f) poor cardiac function: left ventricular ejection fraction under 45% g) poor pulmonary function: DLCO, FEV1 and FVC under 50% h) poor liver function: transaminase more than 3 time of normal level and bilirubin over 2,5 mg/dl (except the Gilbert syndrome) i) poor renal function: elevated creatinine above 1,5 mg/dl. j) curent uncontrolled bacterial, viral or fungal infection k) anti-donor HLA-antibodies defined by positive crossmatch test of any titer rely on complement-dependent cytotoxicity l) evidence of HIV positive serology or infection l) pregnancy and breast-feeding. m) lack of a signed informed consent for the patient and for his donor.
After the patient passed this exclusion criterias he will be screened for HbsAg; anti Hbcore; anti HIV 1,2; HIV1,2 NAT; HCV NAT; HBV NAT; anti-HTLV; anti-HCV; anti-CMV, anti-EBV; antitoxoplasma and serology for syphilis.
Donor selection criterias, in decreasing order of priority:
1. donor must be medically, socially and psychologically fit to donate 2. donor must be HLA-haploidentical first-degree relatives of the patient with signed consent. For donors under 18 years of age a local judge will take the consent, obeying Romanian rules and laws. 3. the maximum recipient actual body weight should not exceed 1,25 times the donor actual body weight. 4. the patient must lack antibodies against donor HLA molecules (specifically complement dependent cytotoxicity) 5. no major ABO incompatibility between donor and recipient ( include: recipient "O" with donor "A", "B" or "AB"; recipient "A" with donor "B" or "AB"; recipient "B" with donor "A" or "AB") 6. matched CMV IgG serologic status between donor and recipient (for a recipient who is CMV negative, use a CMV negative donor; for a positive recipient use a positive donor) 7. use an ABO compatible donor over a minor ABO incompatible donor. 8. other donor characteristics (in no order of priority): preferring donors above 18 years of age over donor under 18; among donors above 18, prefer younger and lighter donor; for male recipients male donors are preferred.
Evaluation of the haplo-identical donor
Haplo-identical bone marrow donor has to be extensively evaluated before donation in order to assess the potential risks to the donor and recipient. Donor eligibility must be documented prior to the start of the preparative regimen for the recipient in the recipient chart. This task will be completed by the transplant physician who will take care of the recipient, under the supervision of Fundeni Clinical Institute transplant committee.
The donor identification must fulfill the following steps: 1. After a patient (recipient) referral to allogeneic transplant setting, HLA typing of the patient and appropriate family members is conducted in an EFI accreditated facility using high-resolution technique. The patient, parents and children are typed at the allelic level for HLA-A, -B,-C,-DRB1 and -DQB1. They will perform also de HLA-antibody search using cross-match test in complement-dependent cytotoxicity. Based on the HLA results and cross-match, potential donors are identified. The laboratory will compose a histocompatibility report and they will submitted this report to Fundeni Clinical Institute transplant committee and it will be attached to the patient medical chart by the transplant physician. 2. When more than one donor is identified, they all are screened using medical history questionnaire, physical examination and laboratory investigations supervised by the transplant physician. The laboratory investigations will be all of the following: CMV status, ABO and Rhesus blood group. He will also generate a report submitted to the Fundeni Clinical Institute transplant committee and attached to the patient medical chart. 3. The transplant committee will discuss and choose the appropriate donor upon the HLA report and clinical status report mentioned at previous two paragraphs. The committee's choise will be attached to the patient medical chart by the transplant physician. 4. The choosed donor than has to be investigated furthermore by the transplant physician as follows: a) verification of HLA typing in a second set of blood-drawn performed for the patient and the identified donor b) the donor will be screened for relevant communicable diseases obeying local policy for: HbsAg; anti Hbcore; anti HIV 1,2; HIV1,2 NAT; HCV NAT; HBV NAT; anti-HTLV; anti-HCV; anti-CMV, anti-EBV; anti-toxoplasma and serology for syphilis. c) the donor will have an EKG, pulmonary radiology and if she is female donor: a pregnancy test. d) the donor will have an anesthesia evaluation at the Anesthesia Department of Fundeni Clinical Institute. All the documentation mentioned above at point 4 will be done by the transplant physician and kept in the patient medical chart.
The conditioning regimen plan and the additional supportive care:
The treatment plan for the haplo-identical transplant setting it is a non-myeloablative conditioning regimen, using the following: In case of lacking TBI procedure at 2 Gy dose in day -1, it could be replaced by two dose of Busulfan iv in day -3 and day-2 (dose=3,2 mg/kgIBW/day) for those with acute and chronic leukemias.
Day
The IBW (ideal body weight) will be calculated using Devine formula and the clearance of creatinine will be calculated using the Cockcroft formula. The fludarabine will be reduced with 20% if de creatinine clearance is below 70 ml/min.
